| |
Monday, December 16, 2024 | 1pm ET / 10am PT Join us for an insightful webinar on the evolving privacy landscape impacting pharma marketers. As state laws continue to shape advertising practices, understanding the nuances of compliance and data ethics is crucial. Register now to gain access to expert insights on sustainable privacy strategies and balancing innovation with ethical data use. 
|
|
Today’s Big NewsDec 13, 2024 |
|
Wednesday, January 15, 2025 | 12pm ET / 9am PT Sort through the noise and hear from Washington Insiders. This session will offer key insights into the economic and political landscape, guiding your company on how best to prepare for and respond to potential changes in funding opportunities and compliance requirements. Register now. 
|
|
| By Gabrielle Masson AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. |
|
|
|
By Kevin Dunleavy McKinsey will pay $650 million to settle with the U.S. Department of Justice, which was investigating the company’s efforts to help Purdue increase its opioid sales. In exchange, the DOJ will drop its charges. |
By Conor Hale The company received a new FDA clearance for the PillCam Genius SB this past May, though the technology has been in use since the early 2000s. |
By Darren Incorvaia Incyte is dropping a program for patients with myelofibrosis-related anemia after its investigational small molecule failed to improve symptoms in a phase 1/2 trial. |
|
The right funding at the right time is crucial for life sciences companies that want to fuel innovation and scale operations. Download this free whitepaper to drive innovation, expand operations and lead your organization to further success. 
|
|
By Kevin Dunleavy An FDA advisory committee—examining the halt of a trial of two Moderna respiratory syncytial virus (RSV) vaccines because of severe lower respiratory tract infections (LRTIs)—echoed frustration in knowledge gaps about the disease and said that more testing is needed. |
By Andrea Park,James Waldron This week on “The Top Line,” we hear from Novo Nordisk CSO Marcus Schindler about his role at the Danish pharma and what’s next for the GLP-1 drug class. |
By James Waldron Editas Medicine is laying off three-quarters of its workforce, including its chief medical officer, after the gene-editing biotech was unable to find a partner for its sickle cell disease medicine. |
By Nick Paul Taylor Avalere Health has moved Amar Urhekar a rung up the corporate ladder, promoting the executive to CEO after a little more than one year as chief operating officer. |
By Nick Paul Taylor Gilead has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the French drugmaker to replace Merdad Parsey, M.D., Ph.D. The appointment reunites Gilead CEO Daniel O’Day with a key member of the oncology team from his time at Roche. |
By Angus Liu In a flurry of decisions Friday, the European Medicines Agency’s human products committee recommended 17 new drugs for approval while letting Takeda withdraw from market an inflammatory bowel disease complication medication. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we hear from Novo Nordisk CSO Marcus Schindler about his role at the Danish pharma and what’s next for the GLP-1 drug class. |
|
|---|
|
|
|
The DMPK experts at QPS are ready to complete your next mass balance,
PK, ADME, MARG and/or QWBA study. Download the DMPK White Paper on the optimal methods of producing tissue distribution data and to learn more about QPS DMPK capabilities. .png)
|
|
Whitepaper We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
